MedTrace Logo

A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718

NCT04087187 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-11-15

No results posted yet for this study

Summary

This study will be conducted to evaluate the AZD5718 pharmacokinetic (PK) doses in order to determine exposure in a new dose range and compare with previous results. This study will include 14 subjects in a single site in United Kingdom. Each subject will be involved in the study for 6 to 7 weeks.

Conditions

Interventions

DRUG

Treatment A

Subject will be given AZD5718 Dose A tablet once daily

DRUG

Treatment B

Subjects will be given AZD5718 Dose B tablet once daily

DRUG

Treatment C

Subjects will be given AZD5718 Dose C tablet once daily

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-20
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04087187 on ClinicalTrials.gov